A generic pharmaceutical company's move to preserve litigation options in case an appellate court reversed its lower court win on one set of grounds was "particularly egregious," the U.S. Court of Appeals for the Federal Circuit has ruled.
Federal Circuit: Cross-appeal by Apotex an 'egregious' attempt to 'game the system'
The National Law Journal
This article requires premium access
This article requires free registration to The National Law Journal. Please sign in or register to read the full text.